Chapter 4: Red cell transfusion to treat anemia in CKD

doi:10.1038/kisup.2012.36

Cited by 11 publications

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regardless of the type of cancer [2,22,29] or other diseases [30][31][32], the red blood cells concentrated and the FFP are the main blood products transfused worldwide. In both cases, the Blood Banks must ensure and organise the cyclical viability of these products.…”

Section: Discussionmentioning

confidence: 99%

Frequency of allogenic blood transfusion in patients with gastrointestinal cancer: a cross-sectional study in Peru

Moya‐Salazar¹,

Cáceres²,

Blejer³

et al. 2021

ecancer

View full text Add to dashboard Cite

Background: Gastrointestinal cancer demands a high frequency of transfusions, and the high availability of blood products. We aimed to determine the frequency of blood transfusions and the most used blood products according to the type of gastrointestinal cancer. Methods:A cross-sectional study was conducted in a Peruvian Type I Hemotherapy and Blood Bank Service of a Private Oncological Clinic during 2016-2018. We included patients with gastrointestinal cancer using the International Code of Diseases. The donations were made in compliance with the requirements of the Programa Nacional de Hemoterapía y Banco de Sangre and in accordance with the Standardised Operational Procedure of the clinic. Results:We analysed 3,022 patients, of which 163 (5.4%) had gastrointestinal cancer (67.1 ± 12 years). The 80 (49.1%) men did not show significant differences with the 83 (50.9%) women (p = 0.178). The most frequent neoplasia was the colon (41.7%) and pancreas (37.4%). Three hundred and four blood products were transfused (average 1.8 ± 2.5 units (range: 1-30 units/patient)), of which 81.3% (247 units) were red blood cells concentrated, 8.6% (26 units) were fresh-frozen-plasma (FFP) and 6.6% (20 units) were cryoprecipitate. The type of cancer that most blood products demanded was colon neoplasia (41.8%), followed by pancreatic cancer (26.3%) and liver cancer (10.9%). We determined that ~55% of patients were O Rh(D)+ and in five patients we were poly-transfused. Conclusion:Our findings suggested that patients with gastrointestinal cancer require large numbers of transfusions of blood cell concentrate and FFP. Also, we showed that cancer of the colon, pancreas and liver demanded more than 75% of blood products.

show abstract

Section: Discussionmentioning

confidence: 99%

Frequency of allogenic blood transfusion in patients with gastrointestinal cancer: a cross-sectional study in Peru

Moya‐Salazar¹,

Cáceres²,

Blejer³

et al. 2021

ecancer

View full text Add to dashboard Cite

show abstract

Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study

et al. 2021

View full text Add to dashboard Cite

Anemia is the predominant cytopenia in myelodysplastic syndromes (MDS) and treatment options are limited. Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor approved for the treatment of anemia of chronic kidney disease in the UK, EU, China, Japan, South Korea, and Chile. MATTERHORN is a phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of roxadustat in anemia of lower risk-MDS. Eligible patients had baseline serum erythropoietin ≤ 400 mIU/mL, and a low packed RBC transfusion burden. In this openlabel (OL), dose-selection, lead-in phase, enrolled patients were assigned to 1 of 3 roxadustat starting doses (n = 8 each): 1.5, 2.0, and 2.5 mg/kg. The primary efficacy endpoint of the OL phase was the proportion of patients with transfusion independence (TI) for ≥ 8 consecutive weeks in the first 28 treatment weeks. A secondary efficacy endpoint was the proportion of patients with a ≥ 50% reduction in RBC transfusions over an 8-week period compared with baseline. Adverse events were monitored. Patients were followed for 52 weeks. Of the 24 treated patients, TI was achieved in 9 patients (37.5%) at 28 and 52 weeks; 7 of these patients were receiving 2.5 mg/kg dose when TI was achieved. A ≥ 50% reduction in RBC transfusions was achieved in 54.2% and 58.3% of patients at 28 and 52 weeks, respectively. Oral roxadustat dosed thrice weekly was well tolerated. There were no fatalities or progression to acute myeloid leukemia. Based on these outcomes, 2.5 mg/kg was the chosen starting roxadustat dose for the ongoing double-blind study phase. | INTRODUCTIONMyelodysplastic syndromes (MDS) affect about 60 000 Americans, with an annual incidence of 4.5 per 100 000 people. [1][2][3] About 77% of patients diagnosed with MDS have a disease that is classified as lower risk (LR-MDS) at diagnosis, as defined by the revised International Prognostic Scoring System (IPSS-R) score of ≤ 3.5. [4][5][6] More than 90% of patients diagnosed with MDS have anemia at the time of their diagnosis, and over 60% of patients with MDS experience severe anemia at later stages of their disease. 7,8 Currently, there are limited anemia treatments with variable response rates approved for patients with LR-MDS in the US and EU for small subsets of LR-MDS patients. Epoetin alfa is approved in Europe for patients with LR-MDS with symptomatic anemia (hemoglobin < 10 g/dL). It was also granted orphan drug designation in the US for the study of adult patients with MDS. Red blood cell Clinical trial registration: NCT03263091.

show abstract

Update on erythropoiesis-stimulating agents

Goodnough

Shander

2013

Best Practice & Research Clinical Anaesthesiology

View full text Add to dashboard Cite

Chapter 4: Red cell transfusion to treat anemia in CKD

Cited by 11 publications

References 51 publications

Frequency of allogenic blood transfusion in patients with gastrointestinal cancer: a cross-sectional study in Peru

Frequency of allogenic blood transfusion in patients with gastrointestinal cancer: a cross-sectional study in Peru

Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study

Update on erythropoiesis-stimulating agents

Contact Info

Product

Resources

About